This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAbout OCTAGAM 10%EfficacyEfficacyDMcITPSafety & TolerabilitySafety & TolerabilityDMcITPDosing & Infusion RatesDosing & Infusion Rates DMcITPSupportSupportMaterialsVideosPfizer OCTAGAM Co-Pay ProgramPfizer IGuide™Ig CompanionFrequently asked questionsRequest a representative

Coverage

Prescribing Information, including BOXED WARNINGIndicationsOCTAGAM 5%Patient Site
SupportGet answers to frequently asked questions about OCTAGAM 10% [Immune Globulin Intravenous (Human) liquid]What are the most common side effects seen with OCTAGAM 10%?

DM in adults
The most common ARs reported in >5% of patients during a clinical study were: headache (42%; 40 of 95), pyrexia (19%; 18 of 95), nausea (16%; 15 of 95), vomiting (8%; 8 of 95), chills (7%; 7 of 95), musculoskeletal pain (7%; 7 of 95), and blood pressure increased (6%; 6 of 95).1

cITP in adults
The most common ARs observed at a rate of >5% in patients in clinical studies were:  headache (25%; 29 of 116), pyrexia (15%; 17 of 116), heart rate increased (11%; 13 of 116).1

Is premedication required with OCTAGAM 10% infusions?

DM study

During the study, 10 of 95 patients (21%) in the OCTAGAM 10% treatment arm received premedication1,2

  • Routine use of premedication was to be avoided, but if a patient had 2 consecutive infusion-related adverse reactions, premedication could be given2

cITP study

During the study, use of premedication to alleviate potential adverse drug reactions was allowed and 0.9% of patients (1 of 116) received premedication.1

Were there any patient withdrawals in the cITP clinical study?

cITP study

No patient withdrew from the cITP study due to a drug-related adverse event2

What vial sizes are available for OCTAGAM 10%?

OCTAGAM 10% is available in 5 vial sizes to help meet the individual dosing needs of patients: 20 mL (2 g), 50 mL (5 g), 100 mL (10 g), 200 mL (20 g), and 300 mL (30 g).1

Where can I get more information about OCTAGAM 10%?

Please contact your Pfizer sales representative
Tel: 1-844-646-4398

Or click here to request a representative.

Medical Information
[email protected]
Tel: 1-888-429-4535

What if my patients cannot tolerate their OCTAGAM 10% infusion and/or infusion rate?

Patients should be carefully monitored throughout the infusion and infusion rate adjusted if adverse drug reactions related to the rate of infusion occur. The Package Insert for OCTAGAM 10% recommends using an appropriate dose the patient can tolerate. For more information about OCTAGAM 10% dosing and infusion rates, click here.

How is OCTAGAM 10% supplied and stored?

OCTAGAM 10% is available in a broad range of presentations, including 2 g, 5 g, 10 g, 20 g, and 30 g single-use bottles.1
 

OCTAGAM 10% may be stored in the refrigerator for 36 months at +36 °F to +46 °F (2 °C to 
8 °C).1

  • Do not freeze. Do not use frozen OCTAGAM 10%
  • OCTAGAM 10% may be stored up to 9 months at room temperature ≤+77 °F (25 °C) within the first 12 months of its shelf life
    • After storage at  ≤+77 °F (25 °C), the product must be used or discarded
What is the IgA content level in OCTAGAM 10%?

The average IgA content level of OCTAGAM 10% is 106 µg/mL. OCTAGAM 10% is contraindicated in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.1

References:Octagam 10%. Prescribing information. Octapharma USA Inc.; 2022.Data on file. Octapharma USA Inc.Support Access resources, including a 
free patient app Access here Loading Ig Companion: Free app for virtual Ig patient supportLearn more about the app Loading OCTAGAM 10% DM clinical results video Watch here Loading Request a representative Request here Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-OTG-USA-0273
You are now leaving PfizerYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-MCL-USA-0367

Indications and Usage

OCTAGAM® 10% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) to rapidly raise platelet counts to control or prevent bleeding in adults and for dermatomyositis (DM) in adults.

Please click here for Full Prescribing Information, including BOXED WARNING.

Indications and Usage OCTAGAM® 10% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) to rapidly raise platelet counts to control or prevent bleeding in adults and for dermatomyositis (DM) in adults. Please click here for Full Prescribing Information, including BOXED WARNING.
IMPORTANT SAFETY
INFORMATION WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE
  • Thrombosis may occur with immune globulin intravenous (IgIV) products, including OCTAGAM 10% liquid. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IgIV products, including OCTAGAM 10% liquid. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IgIV products containing sucrose. OCTAGAM 10% liquid does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer OCTAGAM 10% liquid at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Dosing and Administration Patients with dermatomyositis are at increased risk for thromboembolic events; monitor carefully and do not exceed an infusion rate of 0.04 mL/kg/min. ContraindicationsOCTAGAM 10% liquid is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin and in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.Warnings and PrecautionsOCTAGAM 10% liquid may cause hypersensitivity in patients with a corn allergy. OCTAGAM 10% liquid contains maltose, which is derived from corn. Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure. Falsely elevated blood glucose readings may occur during and after the infusion of OCTAGAM 10% liquid with testing by some glucometers and test strip systems. Hyperproteinemia, increased serum osmolarity, and hyponatremia may occur in patients receiving OCTAGAM 10% liquid. Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to treatment with OCTAGAM 10% liquid. Risk factors for hemolysis include high doses and non–O-blood group. Closely monitor patients for hemolysis and hemolytic anemia. Aseptic meningitis syndrome may occur in patients receiving OCTAGAM 10% liquid, especially with high doses or rapid infusion. Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]). OCTAGAM 10% liquid is made from human plasma and may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease agent. Adverse Reactions cITP - The most common adverse reactions reported in >5% of study subjects were headache, fever, and increased heart rate. DM - The most common adverse reactions reported in >5% of study subjects were headache, fever, nausea, vomiting, increased blood pressure, chills, musculoskeletal pain, increased heart rate, dyspnea, and infusion site reactions.You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.OCTAGAM® is a registered trademark of Octapharma AG.Please click here for Full Prescribing Information, including BOXED WARNING.INDICATIONS AND USAGEOCTAGAM® 10% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) to rapidly raise platelet counts to control or prevent bleeding in adults and for dermatomyositis (DM) in adults.